165 related articles for article (PubMed ID: 12846401)
21. The medical management of primary sclerosing cholangitis.
Cullen SN; Chapman RW
Semin Liver Dis; 2006 Feb; 26(1):52-61. PubMed ID: 16496233
[TBL] [Abstract][Full Text] [Related]
22. Prevention of colon cancer with ursodiol in ulcerative colitis.
Kim HS
Inflamm Bowel Dis; 2001 Aug; 7(3):279-80. PubMed ID: 11515858
[No Abstract] [Full Text] [Related]
23. Case report: anti-proteinase 3 antibody activity in a patient with primary sclerosing cholangitis: clinical remission following ursodeoxycholic acid therapy.
Wong SS; Lawton JW
J Gastroenterol Hepatol; 1996 Dec; 11(12):1161-3. PubMed ID: 9034936
[TBL] [Abstract][Full Text] [Related]
24. [Primary sclerosing cholangitis with itching treated during pregnancy with ursodeoxycholic acid].
Christensen KL; Andersen BN; Vilstrup H
Ugeskr Laeger; 1997 Nov; 159(48):7151-3. PubMed ID: 9417723
[TBL] [Abstract][Full Text] [Related]
25. Primary sclerosing cholangitis in pregnancy refractory to ursodeoxycholic acid treatment: a case report.
Leftwich H; Fang YM; Borgida A; Crombleholme W
J Reprod Med; 2010; 55(11-12):517-9. PubMed ID: 21291041
[TBL] [Abstract][Full Text] [Related]
26. Primary sclerosing cholangitis: updates in diagnosis and therapy.
Portincasa P; Vacca M; Moschetta A; Petruzzelli M; Palasciano G; van Erpecum KJ; van Berge-Henegouwen GP
World J Gastroenterol; 2005 Jan; 11(1):7-16. PubMed ID: 15609388
[TBL] [Abstract][Full Text] [Related]
27. Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials.
Assis DN; Levy C
Hepatology; 2021 Mar; 73(3):887-889. PubMed ID: 33403699
[No Abstract] [Full Text] [Related]
28. Treatment of Severe Hypercholesterolemia in a Woman With Advanced Primary Sclerosing Cholangitis.
Xiao C; Hegele RA; Lewis GF
JAMA Cardiol; 2017 May; 2(5):575-576. PubMed ID: 28384790
[No Abstract] [Full Text] [Related]
29. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey.
Okolicsanyi L; Groppo M; Floreani A; Morselli-Labate AM; Rusticali AG; Battocchia A; Colombo M; Galatola G; Gasbarrini G; Podda M; Ricci G; Rosina F; Zuin M
Dig Liver Dis; 2003 May; 35(5):325-31. PubMed ID: 12846404
[TBL] [Abstract][Full Text] [Related]
30. [Ischemic cholangitis in intensive care unit: favourable outcome with ursodesoxycholic acid and fenofibrate].
Bélénotti P; Guervilly C; Grandval P; Benyamine A; Ene N; Serratrice J; Petit P; Laugier R; Papazian L; Weiller PJ
Rev Med Interne; 2013 Feb; 34(2):110-3. PubMed ID: 23200798
[TBL] [Abstract][Full Text] [Related]
31. Primary sclerosing cholangitis and bile acids.
Chazouillères O
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S21-5. PubMed ID: 23141889
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
Triantos CK; Koukias NM; Nikolopoulou VN; Burroughs AK
Aliment Pharmacol Ther; 2011 Oct; 34(8):901-10. PubMed ID: 21883323
[TBL] [Abstract][Full Text] [Related]
33. [Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
Stiefelhagen P
MMW Fortschr Med; 2007 May; 149(21):49. PubMed ID: 17668736
[No Abstract] [Full Text] [Related]
34. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR
J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives.
Serfaty L; Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S1. PubMed ID: 23141887
[No Abstract] [Full Text] [Related]
36. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
Wolf JM; Rybicki LA; Lashner BA
Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
[TBL] [Abstract][Full Text] [Related]
37. Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research.
Hawk ET; Viner JL
Ann Intern Med; 2001 Jan; 134(2):158-60. PubMed ID: 11177320
[No Abstract] [Full Text] [Related]
38. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.
Pardi DS; Loftus EV; Kremers WK; Keach J; Lindor KD
Gastroenterology; 2003 Apr; 124(4):889-93. PubMed ID: 12671884
[TBL] [Abstract][Full Text] [Related]
39. Novel developments in IBD-related sclerosing cholangitis.
Ponsioen CY
Best Pract Res Clin Gastroenterol; 2011 Apr; 25 Suppl 1():S15-8. PubMed ID: 21640925
[TBL] [Abstract][Full Text] [Related]
40. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
